202 related articles for article (PubMed ID: 15942100)
1. High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement.
Shimojima Y; Matsuda M; Ishii W; Koyama J; Yamamoto K; Shimodaira S; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):484-9. PubMed ID: 15942100
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
3. AL amyloidosis manifesting as systemic lymphadenopathy.
Matsuda M; Gono T; Shimojima Y; Yoshida T; Katoh N; Hoshii Y; Yamada T; Ikeda S
Amyloid; 2008 Jun; 15(2):117-24. PubMed ID: 18484338
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
5. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
6. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
[TBL] [Abstract][Full Text] [Related]
7. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
Sanchorawala V
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
[TBL] [Abstract][Full Text] [Related]
8. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
Amyloid; 2009 Dec; 16(4):243-5. PubMed ID: 19922338
[TBL] [Abstract][Full Text] [Related]
9. [Three patients with primary AL amyloidosis treated by high-dose melphalan with autologous peripheral blood stem cell transplantation].
Mukai S; Kanashima H; Ogawa Y; Nakao T; Teshima H; Yamane T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):625-7. PubMed ID: 22504689
[TBL] [Abstract][Full Text] [Related]
10. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
[TBL] [Abstract][Full Text] [Related]
11. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection.
Gono T; Matsuda M; Shimojima Y; Ishii W; Koyama J; Sakashita K; Koike K; Hoshii Y; Ikeda S
Amyloid; 2004 Dec; 11(4):245-56. PubMed ID: 15678759
[TBL] [Abstract][Full Text] [Related]
12. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis.
Nelson LM; Gustafsson F; Gimsing P
Acta Haematol; 2015; 133(4):336-46. PubMed ID: 25531398
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation.
Yamazaki O; Ubara Y; Suwabe T; Nakanishi S; Hoshino J; Sawa N; Hayami N; Yamanouchi M; Takemoto F; Kenmei T; Masuoka K; Oohashi K
Clin Exp Nephrol; 2009 Oct; 13(5):522-525. PubMed ID: 19499180
[TBL] [Abstract][Full Text] [Related]
15. High-dose melphalan and autologous peripheral blood stem cell transplantation in patients with AL amyloidosis and cardiac defibrillators.
Phull P; Sanchorawala V; Brauneis D; Sloan JM; Siddiqi OK; Quillen K; Sarosiek S
Bone Marrow Transplant; 2019 Aug; 54(8):1304-1309. PubMed ID: 30664726
[TBL] [Abstract][Full Text] [Related]
16. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
17. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
20. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]